Advisors Asset Management Inc. Has $3.11 Million Stock Holdings in The Cooper Companies, Inc. (NASDAQ:COO)

Advisors Asset Management Inc. lessened its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 2.2% during the 4th quarter, HoldingsChannel reports. The firm owned 33,870 shares of the medical device company’s stock after selling 769 shares during the quarter. Advisors Asset Management Inc.’s holdings in Cooper Companies were worth $3,114,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in COO. Byrne Asset Management LLC acquired a new position in Cooper Companies during the fourth quarter valued at approximately $33,000. OFI Invest Asset Management acquired a new stake in shares of Cooper Companies in the fourth quarter worth $34,000. Brown Brothers Harriman & Co. grew its stake in shares of Cooper Companies by 191.0% in the third quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after acquiring an additional 275 shares during the last quarter. West Financial Advisors LLC acquired a new stake in shares of Cooper Companies in the fourth quarter worth $49,000. Finally, Atala Financial Inc acquired a new stake in shares of Cooper Companies in the fourth quarter worth $51,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on COO. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research note on Friday, March 7th. StockNews.com downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Morgan Stanley lowered their price objective on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. Wells Fargo & Company raised their target price on Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research report on Friday, December 6th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $115.00 target price (down from $120.00) on shares of Cooper Companies in a research report on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Cooper Companies currently has a consensus rating of “Moderate Buy” and an average price target of $110.25.

Cooper Companies Stock Up 1.6 %

Shares of NASDAQ COO opened at $81.71 on Friday. The stock has a market cap of $16.34 billion, a PE ratio of 41.90, a PEG ratio of 2.25 and a beta of 1.02. The business has a fifty day moving average of $90.05 and a two-hundred day moving average of $98.14. The Cooper Companies, Inc. has a 52-week low of $77.05 and a 52-week high of $112.38. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.92. The company had revenue of $964.70 million during the quarter, compared to analysts’ expectations of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. As a group, equities research analysts expect that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.